Pediatric diffuse intrinsic pontine gliomas
Conditions
Interventions
Control Group 1:None Treatment
Control Group 2:Radiation therapy (60Gy)
Test Group:Radiation therapy (60Gy) + Niraparib (100 mg/d)
Sponsors
The Third Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
3 Years to 16 Years
Inclusion criteria
Inclusion criteria: a.Patients with newly diagnosed H3K27M mutant DIPG, age must be = 3 years of age and = 16 years of age at the time of study entry for patients diagnosed with DIPGall sexes eligible. b.DIPG patients must have been biopsied and accepted standard radiation therapy. c.DIPG patients haven't received any chemotherapy, immunotherapy and other treatment. d.Lansky score = 50, normal organ function, normal Blood routine test and so on. e.Voluntary and sign a consent form.
Exclusion criteria
Exclusion criteria: a.No H3K27M mutant DIPG, recurrent DIPG. b.Patients with uncontrollable infectious disease. c.Have other malignant tumor history. d.Unable to tolerate radiotherapy. e.Other reasons that are not suitable to participate in this study according to the researcher's judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival;Side Effect;Volume of the Tumor;KPS; | — |
Secondary
| Measure | Time frame |
|---|---|
| progress free of survival; | — |
Countries
China
Contacts
Public ContactXinjun Wang
The Third Affiliated Hospital of Zhengzhou University
Outcome results
None listed